
Ruben Mesa/vjhemonc.com
Jun 12, 2025, 10:33
ecancer – Ruben Mesa on Ropeginterferon’s Superiority in SURPASS-ET Trial
ecancer posted on X:
“The Phase 3 SURPASS-ET trial evaluates ropeginterferon alfa-2b versus anagrelide in patients with essential thrombocythaemia. Ropeginterferon shows superior safety and efficacy compared to anagrelide.
Watch full interview with Dr Ruben Mesa.”
More posts featuring Ruben Mesa.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 12, 2025, 10:33
Jun 12, 2025, 10:30
Jun 12, 2025, 10:17
Jun 12, 2025, 10:08
Jun 12, 2025, 10:06
Jun 12, 2025, 09:55